Literature DB >> 25548550

Heterogeneity in active surveillance protocols worldwide.

Stacy Loeb, H Ballentine Carter1, Mark Schwartz2, Angela Fagerlin, R Scott Braithwaite2, Herbert Lepor3.   

Abstract

Year:  2014        PMID： 25548550      PMCID： PMC4274180     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  7 in total

1.  Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists.

Authors:  M A Gorin; A Eldefrawy; O Ekwenna; M S Soloway
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-12-06       Impact factor: 5.554

2.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.

Authors:  Patricia A Ganz; John M Barry; Wylie Burke; Nananda F Col; Phaedra S Corso; Everett Dodson; M Elizabeth Hammond; Barry A Kogan; Charles F Lynch; Lee Newcomer; Eric J Seifter; Janet A Tooze; Kasisomayajula Viswanath; Hunter Wessells
Journal:  Ann Intern Med       Date:  2012-02-20       Impact factor: 25.391

3.  Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Anna Kettermann; Patricia Landis; Debra J Elliot; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Lori J Sokoll
Journal:  J Urol       Date:  2009-12-14       Impact factor: 7.450

4.  Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Zhaoyong Feng; Sumit Isharwal; Patricia Landis; Debra J Elliot; Robert Veltri; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Bruce Trock; Lori J Sokoll
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

5.  Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.

Authors:  Stacy Loeb; Anders Berglund; Pär Stattin
Journal:  J Urol       Date:  2013-05-30       Impact factor: 7.450

6.  Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.

Authors:  Daniel W Lin; Lisa F Newcomb; Elissa C Brown; James D Brooks; Peter R Carroll; Ziding Feng; Martin E Gleave; Raymond S Lance; Martin G Sanda; Ian M Thompson; John T Wei; Peter S Nelson
Journal:  Clin Cancer Res       Date:  2013-03-20       Impact factor: 12.531

7.  The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort.

Authors:  Hiromi Hirama; Mikio Sugimoto; Kazuto Ito; Taizo Shiraishi; Yoshiyuki Kakehi
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-19       Impact factor: 4.553
  7 in total
  7 in total

1.  Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.

Authors:  Stacy Loeb; Qinlian Zhou; Uwe Siebert; Ursula Rochau; Beate Jahn; Nikolai Mühlberger; H Ballentine Carter; Herbert Lepor; R Scott Braithwaite
Journal:  Eur Urol       Date:  2017-08-23       Impact factor: 20.096

2.  Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.

Authors:  Liam C Macleod; Jonathan G Yabes; Mina M Fam; Jathin Bandari; Michelle Yu; Avinash Maganty; Alessandro Furlan; Christopher P Filson; Benjamin J Davies; Bruce L Jacobs
Journal:  Eur Urol Focus       Date:  2019-04-25

3.  Qualitative study on decision-making by prostate cancer physicians during active surveillance.

Authors:  Stacy Loeb; Caitlin Curnyn; Angela Fagerlin; Ronald Scott Braithwaite; Mark D Schwartz; Herbert Lepor; Herbert Ballentine Carter; Erica Sedlander
Journal:  BJU Int       Date:  2016-10-02       Impact factor: 5.588

Review 4.  Biomarkers in active surveillance.

Authors:  Stacy Loeb; Jeffrey J Tosoian
Journal:  Transl Androl Urol       Date:  2018-02

5.  Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs.

Authors:  Anirudh Tomer; Dimitris Rizopoulos; Daan Nieboer; Frank-Jan Drost; Monique J Roobol; Ewout W Steyerberg
Journal:  Med Decis Making       Date:  2019-07-18       Impact factor: 2.583

6.  Shared decision making of burdensome surveillance tests using personalized schedules and their burden and benefit.

Authors:  Anirudh Tomer; Daan Nieboer; Monique J Roobol; Ewout W Steyerberg; Dimitris Rizopoulos
Journal:  Stat Med       Date:  2022-02-10       Impact factor: 2.497

7.  Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.

Authors:  Anirudh Tomer; Daan Nieboer; Monique J Roobol; Anders Bjartell; Ewout W Steyerberg; Dimitris Rizopoulos
Journal:  BJU Int       Date:  2020-08-01       Impact factor: 5.588
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.